Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
LifeMD, a telehealth company, has expanded its primary care platform by offering free at-home screening kits for early detection of colon and breast cancer. The Aware® Breast Self Exam pad and EZ Detect™ at-home test are designed to empower patients in proactive health management. This initiative is part of LifeMD's commitment to enhancing diagnostic capabilities and preventive care through strategic partnerships. The kits will be available free with a LifeMD membership, reinforcing the importance of early detection in successful treatment outcomes.
LifeMD (NASDAQ: LFMD) announces a strategic partnership between its allergy telehealth subsidiary, Cleared, and Allergenis, aiming to enhance food allergy management. Cleared will serve as the exclusive telehealth provider for Allergenis' breakthrough peanut allergy diagnostic blood test, which boasts a 93% accuracy rate and eliminates the need for risky oral food challenges. With an estimated 32 million Americans affected by food allergies, this collaboration seeks to address the long wait times for allergist appointments and improve access to essential allergy testing.
LifeMD reported record consolidated revenue of $30.5 million for Q2 2022, a 37% increase from the previous year. Adjusted EPS improved 52% to $(0.22). The company expects to achieve Adjusted EBITDA profitability by Q4 2022, with Adjusted EBITDA loss reduced to below $1 million in June. Subscriber numbers rose 53% to 168,000, while gross margins reached 85%. LifeMD anticipates consolidated revenue guidance of $122 to $128 million for the year, driven by growth in telehealth services and the planned divestiture of WorkSimpli.
LifeMD, a direct-to-patient telehealth company, will report its Q2 financial results on August 11, 2022, after market close. A conference call for investors is scheduled for the same day at 4:30 PM ET to discuss the results and provide updates. LifeMD operates in all 50 states and offers virtual healthcare services, including primary care and specialized treatments, leveraging its technology and nationwide pharmacy network.
LifeMD has announced a major expansion of its Virtual Primary Care platform, now addressing over 200 common medical conditions, including COVID. The company's CEO, Justin Schreiber, highlights the potential for growth and the impact on American healthcare. The platform enables patients to access treatments and prescription medications affordably, showcasing a shift from product-oriented telehealth to full-spectrum care. LifeMD aims to enhance healthcare accessibility through its proprietary technology and nationwide pharmacy network.
LifeMD, a direct-to-patient telehealth company, has declared a cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP). This dividend is set for payment on July 15, 2022, to the shareholders who are on record by the close of business on July 5, 2022.
LifeMD aims to enhance healthcare access through a portfolio of services including virtual primary care, diagnostics, and specialized treatments.
LifeMD, Inc. (NASDAQ: LFMD) reported a 60% increase in first quarter 2022 revenue, reaching $29.0 million, driven by a 70% surge in telehealth services. Adjusted EPS improved by 14% sequentially to $(0.25). The company maintains its goal of achieving Adjusted EBITDA profitability by Q4 2022, with a cash balance of $25.1 million and no debt. Significant acquisitions were completed, and operational efficiencies were noted, despite advertising market challenges. The Q1 results illustrate LifeMD's strategic growth plans and operational scaling.
LifeMD, Inc. (NASDAQ: LFMD) announced that it will release its financial results for Q1 2022 on May 13, 2022, before market open. The company will host a conference call at 8:00 AM ET the same day to discuss these results and provide a corporate update. LifeMD is a telehealth company offering virtual primary care and specialized treatments across all 50 states, leveraging technology and a nationwide pharmacy network to enhance healthcare accessibility.
LifeMD, a prominent telehealth company, will participate in two key conferences: the H.C. Wainwright Conference from May 23–26, 2022, featuring on-demand presentations and one-on-one meetings, and the B. Riley Securities 22nd Annual Institutional Investor Conference on May 26, 2022, at 11:50 AM ET. Investors can register for these events through provided links. LifeMD continues to enhance access to affordable healthcare via its virtual services across the U.S., catering to various health needs.
LifeMD, Inc. (NASDAQ: LFMD), a prominent telehealth provider, announced its participation in the 21st Annual Needham Virtual Healthcare Conference scheduled for April 11-14, 2022. The company will present on April 13 at 3:00 PM ET and will offer one-on-one meetings for investors. LifeMD provides a wide range of telehealth services across all 50 states, focusing on primary care, diagnostics, and specialized treatments. The company's goal is to enhance access to affordable healthcare through its technology platform and mail-order pharmacy network.